Adam Litterman

Title: The Innovative Contributions of Adam Litterman

Introduction

Adam Litterman is an inventive figure located in San Francisco, California. With a focus on advancing the field of immunology, he holds a significant patent that showcases his commitment to developing cutting-edge solutions in medical technology.

Latest Patents

Litterman is credited with a patent titled "Immune cells having co-expressed shRNAS and logic gate systems." This innovative patent outlines the use of recombinant nucleic acids that encode chimeric priming receptors binding to ALPG/P, chimeric antigen receptors targeting MSLN, and shRNA that specifically target FAS, PTPN2, and/or TOX. The patent further details systems of these chimeric priming receptors, the corresponding cells expressing such proteins and shRNA, and methods for utilizing this groundbreaking technology.

Career Highlights

Currently, Adam Litterman is part of Arsenal Biosciences, Inc., where he continues to contribute to pioneering research in the field. His work reflects a blend of scientific expertise and innovative thinking, positioning him as a noteworthy inventor within the biotech arena.

Collaborations

Throughout his career, Litterman has collaborated with talented professionals such as Jasper Williams and Michelle Nguyen. These partnerships have fostered a creative environment that encourages the exploration of novel approaches to complex biological challenges.

Conclusion

Adam Litterman's contributions to the field of immunology exemplify the spirit of innovation that drives advancements in medical technology. With his remarkable patent and collaborative endeavors, he remains a significant player in the development of transformative solutions for healthcare.